Evidence map›Paper›PMID 40561380›Full record

ReviewNeurology2025

Principles for Novel Neurologic Therapeutics: An AAN Position Statement.

Larry B Goldstein, Jonathan R Crowe, Anindita Deb, Justin T Jordan, Jonathan D Santoro, James J Sejvar, Madeline Turbes, Robert E Shapiro

Abstract readReviewConsensus Statement
In one paragraph

Review in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Larry B GoldsteinDepartment of Neurology, University of Kentucky, Lexington.ORCID 0000-0001-7747-128X
Jonathan R CroweDepartment of Neurology, University of Virginia, Charlottesville.ORCID 0000-0003-3670-5566
Anindita DebUniversity of Massachusetts, T.H. Chan School of Medicine, Worcester, MA.
Justin T JordanDepartment of Neurology, Massachusetts General Hospital, Boston.ORCID 0000-0001-6198-817X
Jonathan D SantoroDivision of Neurology, Department of Pediatrics, Children's Hospital Los Angeles, CA.ORCID 0000-0002-8350-8234
James J SejvarDepartment of Neurology, University of Pittsburgh, PA.
Madeline TurbesStaff Liaison, American Academy of Neurology, Minneapolis, MN; and.ORCID 0009-0000-9932-5304
Robert E ShapiroDepartment of Neurological Sciences, University of Vermont, Burlington.ORCID 0000-0002-7401-0514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This statement provides general principles of the American Academy of Neurology's (AAN) approach when invited to provide guidance to policymakers on a variety of types of therapies that may have neurologic treatment benefits, but for which available evidence is limited or for which there is no US Food and Drug Administration-approved indication. In these instances, the AAN recommends an approach in which the patient and neurologist carefully review all available evidence and discuss the potential risks and benefits of the therapy, including when patients are contemplating asserting their right to try.

Indexed as

Nervous System DiseasesNeurologyHumansSocieties, MedicalUnited States

Identifiers

PMID40561380
PMCPMC12203596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.